Orkambi and Sputum increased - a phase IV clinical study of FDA data

Summary:

Sputum increased is reported as a side effect among people who take Orkambi (ivacaftor; lumacaftor), especially for people who are female, 10-19 old, have been taking the drug for < 1 month also take Pulmozyme, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Sputum increased when taking Orkambi. It is created by eHealthMe based on reports of 9,494 people who have side effects when taking Orkambi from the FDA, and is updated regularly.

What is Orkambi?

Orkambi has active ingredients of ivacaftor; lumacaftor. eHealthMe is studying from 9,496 Orkambi users. Check the latest studies of Orkambi.

What is Sputum increased?

Sputum increased is found to be associated with 429 drugs and 357 conditions by eHealthMe. Check the latest studies of Sputum increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

9,494 people reported to have side effects when taking Orkambi.
Among them, 63 people (0.66%) have Sputum increased.

Among these 63 people:

How long have people been on Orkambi when they have Sputum increased? *

What is the gender of people who have Sputum increased when taking Orkambi? *

female: 52.54 %
male: 47.46 %

What is the age of people who have Sputum increased when taking Orkambi? *

What are other drugs people take besides Orkambi? *

What are other side effects people have besides Sputum increased? *

Cough: 35 people, 55.56%
Dyspnea (difficult or laboured breathing): 24 people, 38.10%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 18 people, 28.57%
Fever: 18 people, 28.57%
Fatigue (feeling of tiredness): 15 people, 23.81%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 14 people, 22.22%
Nausea And Vomiting: 12 people, 19.05%
Headache (pain in head): 9 people, 14.29%
Pulmonary Function Test Decreased: 9 people, 14.29%
Chest Pain: 7 people, 11.11%

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 63 people, 100.00%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 10 people, 15.87%
Sinusitis (inflammation of sinus): 9 people, 14.29%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 9 people, 14.29%
Constipation: 7 people, 11.11%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 7 people, 11.11%
Cough: 6 people, 9.52%
Sinus Disorder (disease of sinus): 5 people, 7.94%
Rickets (softening of bones): 5 people, 7.94%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 5 people, 7.94%

* Approximation only. Some reports may have incomplete information.

Do you take Orkambi and have Sputum increased?

- Check whether Sputum increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Orkambi:

Orkambi (9,496 reports)

Browse all side effects of Orkambi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sputum increased:

Sputum increased (429 drugs)

Browse all the conditions that are associated with Sputum increased:

Sputum increased (357 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ivacaftor; lumacaftor (the active ingredients of Orkambi) and Orkambi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.